BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.nebraska.edu

Clinical Trials

Factors Affecting Aqueous Humor Outflow Facility in Patients With Uveitis

Withdrawn

Conditions: UVeitis
Glaucoma

First Posted Date: 2015-11-24

Last Posted Date: 2023-08-14

Lead Sponsor: University of Nebraska

Registration Number: NCT02613442

Optimal Stent Selection for the Femoropopliteal Artery

Terminated

Conditions: Femoropopliteal Stenting

Interventions: Other: follow-up CTA

First Posted Date: 2015-11-11

Last Posted Date: 2023-08-29

Lead Sponsor: University of Nebraska

Target Recruit Count: 5

Registration Number: NCT02602145

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Balance Training for Elders With Heart Failure

Not Applicable

Completed

Conditions: Heart Failure

Interventions: Other: Balance Intervention

First Posted Date: 2015-10-02

Last Posted Date: 2023-09-25

Lead Sponsor: University of Nebraska

Target Recruit Count: 33

Registration Number: NCT02566785

Locations: 🇺🇸
University of Nebraska Medical Center, College of Nursing, Lincoln, Nebraska, United States

Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive
Anaplastic Large Cell Lymphoma, ALK-Negative
Stage II Angioimmunoblastic T-cell Lymphoma
Stage IV Enteropathy-Associated T-Cell Lymphoma
Stage III Angioimmunoblastic T-cell Lymphoma
Stage IV Angioimmunoblastic T-cell Lymphoma
Stage II Enteropathy-Associated T-Cell Lymphoma
Hepatosplenic T-Cell Lymphoma
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Stage III Enteropathy-Associated T-Cell Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Prednisone
Drug: Vincristine Sulfate

First Posted Date: 2015-09-28

Last Posted Date: 2023-12-13

Lead Sponsor: University of Nebraska

Target Recruit Count: 54

Registration Number: NCT02561273

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸
University of Colorado Cancer Center, Anschutz Cancer Pavilion, Aurora, Colorado, United States

and more 5 locations

Simplified Diet Approach in Phenylketonuria

Not Applicable

Completed

Conditions: Phenylketonuria

Interventions: Behavioral: Dietary Protein Counting and Free Fruits and Vegetables

First Posted Date: 2015-09-21

Last Posted Date: 2023-09-07

Lead Sponsor: University of Nebraska

Target Recruit Count: 33

Registration Number: NCT02555579

Locations: 🇺🇸
Children's Hospital & Medical Center, Omaha, Nebraska, United States
🇺🇸
Monroe-Meyer Insititute, Omaha, Nebraska, United States
🇺🇸
Nebraska Medicine, Midtown Health Center, Omaha, Nebraska, United States

and more 1 locations

Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency

Not Applicable

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia
Untreated Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Vitamin D Deficiency

Interventions: Dietary Supplement: Cholecalciferol
Other: Laboratory Biomarker Analysis

First Posted Date: 2015-09-17

Last Posted Date: 2024-10-08

Lead Sponsor: University of Nebraska

Target Recruit Count: 197

Registration Number: NCT02553447

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2

Terminated

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Capecitabine
Drug: Docetaxel
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2015-08-14

Last Posted Date: 2023-09-08

Lead Sponsor: University of Nebraska

Target Recruit Count: 14

Registration Number: NCT02524275

Locations: 🇺🇸
Omaha Veterans Administration Medical Center, Omaha, Nebraska, United States
🇺🇸
Faith Regional Health Services Carson Cancer Center, Norfolk, Nebraska, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Influence of Exercise on the Mobility and Balance of Individuals With Multiple Sclerosis

Not Applicable

Completed

Conditions: Multiple Sclerosis

Interventions: Behavioral: Therapeutic Exercise Program
Behavioral: Therapeutic Challenge Program

First Posted Date: 2015-08-14

Last Posted Date: 2023-09-05

Lead Sponsor: University of Nebraska

Target Recruit Count: 32

Registration Number: NCT02524483

Locations: 🇺🇸
Unversity of Nebraska Medical Center, Monroe-Meyer Institute, Omaha, Nebraska, United States

Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study

Phase 2

Withdrawn

Conditions: Diabetic Macular Edema

Interventions: Drug: Ranibizumab
Drug: Tocilizumab

First Posted Date: 2015-07-29

Last Posted Date: 2023-08-15

Lead Sponsor: University of Nebraska

Registration Number: NCT02511067

Treatment of Severe Destructive Behavior: FCT Versus Wait-List Control

Not Applicable

Terminated

Conditions: Aggression
Self-Injurious Behavior

Interventions: Behavioral: Functional Communication Training

First Posted Date: 2015-06-29

Last Posted Date: 2023-09-18

Lead Sponsor: University of Nebraska

Target Recruit Count: 4

Registration Number: NCT02483572

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy